Investor Update

Basel, 20 July 2010

Roche launches new immunoassay module for large volume laboratories

New cobas e 602 module allows customers to integrate immunoassay and clinical chemistry testing on a single platform

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the cobas e 602 module for immunoassay testing as the latest addition to its cobas 8000 platform. This product is now available in Europe as well as in all countries recognizing the CE Mark in the Latin America and Asia-Pacific regions*.

Including Roche’s latest biomarker tests, the immunoassay module runs more than 80 different immunoassays – from high medical value tests for cardiac and infectious diseases to bone markers, rheumatoid arthritis, tumor markers and tests for maternal care – with a throughput of 170 tests / hour. Roche now offers 7 additional configurations to the cobas 8000 modular analyzer series by combining the previously launched clinical chemistry modules with the immunoassay module for serum work area testing.

“With the recent launch of the clinical chemistry modules cobas c 701 and c502, we set a new standard in efficiency for high volume testing. The e602 module will further enhance our customers testing capability by seamlessly integrating clinical chemistry and immunoassay tests in one system,” said Daniel O’Day, Chief Operating Officer of Roche Diagnostics. “Thanks to its broad test menu, combined with an optimised workflow, the new cobas e 602 module will further strengthen our offering in the serum work area segment.”

The cobas 8000 modular analyzer series is the newest member of Roche’s cobas modular platform family. It is designed to meet the needs of high volume laboratories with about 3 to 15 million test per year to deliver high quality results fast and efficiently from a single patient sample. cobas 8000 compliments the cobas 6000 modular analyzer for medium-sized laboratories and the cobas 4000 systems for small workloads.

At around 15 billion USD, the serum work area market is one of the largest segments in in vitro diagnostics.

About the cobas 8000 modular analyzer series

With the launch of the high volume immunochemistry module, customers can consolidate clinical chemistry and immunochemistry testing in many different ways into one single configuration. Not only does cobas 8000 modular analyzer series offer 19 different configurations, it has many innovative design and process elements such as the Module Sample Buffer in each module, independent transport and return lines, switch gates and many more features optimizing sample routing to achieve maximum efficiency and productivity. Also this newest member of the cobas modular platform family uses the same operator interface, detection technologies and reagents as other cobas instruments, enabling standardization of results between different analyzers.

In the coming months, Roche will continue to enhance the cobas 8000 modular analyzer series by introducing a new clinical chemistry module, the cobas c 702 module and offering even more configurations. The cobas c 702 module incorporates an innovative reagent manager allowing for intelligent continuous reagent cassette management without interruption of the workflow for even more efficiency and productivity in high volume laboratories.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

* The cobas 8000 modular analyzer series is not available for use in the United States.